In 2014, the backlog of pending drugs in China rose by one third

By the end of 2014, there were more than 18500 drugs waiting to be approved in China, a third higher than last year On Friday (March 13), officials at the drug review center expressed concern that approval of drugs in the Chinese market would become increasingly difficult A senior executive at a pharmaceutical company believes that China's new drug approval process has become rigid, and companies need to wait six to eight years to enter the world's second largest pharmaceutical market According to IMS Health data, consumption in the Chinese pharmaceutical market will reach US $185 billion by 2018 For pharmaceutical companies, hospital medical equipment companies and operators, China's rapidly growing medical market is undoubtedly full of great attraction By 2020, China's health care consumer market will be a huge one trillion US dollars According to the annual report of the drug review center, in 2014, China drug test center received 8868 new drug applications, of which the receiving volume of chemical drug review tasks increased significantly, while that of traditional Chinese medicine and biological drugs decreased The technical review of 5261 drug registration applications has been completed, an increase of 12.9% over the review completed in 2013 The center said that last year, it completed the number of reviews and recruited a group of experts with rich experience in the industry, but the speed of review is not up to the speed of new drugs to be reviewed, which is equivalent to further backlog of drugs to be reviewed According to Thomson Reuters data, China's medical industry has always been a hot spot for investment and transaction Last year, related transactions doubled to $18.5 billion From this year on, the pace of development will continue to accelerate.